GPR40, GPR84[1] 体内研究PBI-4050是中链长度脂肪酸的合成类似物,与FFA受体1(FFAR1/GPR40)和GPR84结合。为了确定PBI-4050对糖尿病肾病的潜在作用,使用了2型糖尿病肾病的加速模型eNOS -/- db/db小鼠。用8-20周龄的每日管饲法用载体或PBI-4050(100mg/kg)处理小鼠。 eNOS -/- db/db小鼠是中度高血压,PB...
PBI-4050, a GPR40 agonist/GPR84 antagonist, displays anti-fibrotic, anti-inflammatory and anti-proliferative activities.Hypothesis: We evaluated PBI-4050 for the treatment of PH in a HFrEF model and investigated its effect on the expression of profibrotic markers in TGF-β-stimulated human lung ...
setogepram sodium salt is an orally active gpr40 agonist and is an antagonist or inverse agonist for gpr84, with anti-fibrotic, anti-inflammatory and anti-proliferative actions. 价格:￥电议型 号:T12375产 地:美洲 T12883Fezagepras;3-戊基苯乙酸PBI-4050|||Setogepram;PBI-4050|||3-戊基苯乙酸...
PBI-4050 is a dual GPR40 agonist/GPR84 antagonist with antifibrotic and antiproliferative activities.Hypothesis: The aim was to evaluate PBI-4050 in comparison with sildenafil in the angio-proliferative model of Hypoxia/Sugen (HS) PAH. Additionally, mechanistic effects of PBI-4050 were assessed in...
PBI-4050 is a first-in-class dual GPR40 (agonist)/GPR84 (antagonist) receptors modulator. Administered late (2 weeks) after myocardial infarction (MI), PBI-4050 reduces PH, RVH and lung fibrosis.Hypothesis: PBI-4050 administered early after large MI does not adversely affect scar healing and...
PBI-4050, a dual GPR40 agonist/GPR84 antagonist with anti-fibrotic and anti-proliferative activities, is a lead drug candidate in pivotal phase 2/3 clinical trial for IPF.Hypothesis: We evaluated the therapeutic efficacy of PBI-4050 for the treatment of PAH in the hypoxia-Sugen (HS) model,...